CareDx (CDNA) just delivered a quarterly update that combined higher third quarter revenue and net income with an increased full year 2026 revenue outlook, giving investors fresh information to reassess the stock.
The third quarter update lands after a powerful run in the stock, with CareDx’s share price delivering a 94.44% return over 90 days and a 362.23% share price return year to date. The 1 year total shareholder return is very large, signalling momentum that investors are now weighing against the upgraded 2026 outlook and recent AlloSure Kidney clinical data.
Spot opportunities that may reflect similar momentum to CareDx by exploring our hand-picked 34 healthcare AI stocks, which connect medical science with advanced data and diagnostics.Bulls point to CareDx’s rapid earnings swing and raised 2026 revenue range, while bears focus on how much optimism is now in the price. Which side does the current valuation actually support?
Most Popular Narrative: 38% Overvalued
CareDx last closed at $88.47, while the most followed valuation story pegs fair value at $64.17. That narrative frames the recent surge as stretching well beyond its own estimate and puts the spotlight on whether execution can keep up with expectations.
Significant progress in payer coverage including millions of new covered lives, expanded in-network status, and the implementation of a unique CPT code for AlloSure indicates a catalyst for sustained increases in ASP (average selling price) and recurring revenue streams, which can directly enhance future profitability and margin expansion.
See why 8 investors see CareDx as 38% overvalued.
Result: Fair Value of $64.17 (OVERVALUED)
Still, shifting Medicare reimbursement policies and the draft LCD proposals on bundled payments, along with execution risk around Naveris integration, could quickly challenge that upbeat CareDx narrative.
Find out about the key risks to this CareDx narrative.
Another View: Cash Flows Tell A Different CareDx Story
Analysts looking at CareDx through earnings multiples see a rich valuation, yet the SWS DCF model points the other way. At $88.47, the shares sit about 23.5% below an estimated future cash flow value of $115.59, which frames the stock as undervalued on that lens. Which signal do you trust more: the crowd on earnings or the cash flow math?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CareDx for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 35 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Mixed signals on CareDx so far. If the push and pull between risks and upside feels unresolved, pull up the numbers yourself, pressure test the assumptions, and then weigh the 2 key rewards and 3 important warning signs.
Looking for more investment ideas beyond CareDx?
If CareDx has sharpened your thinking, use the same disciplined approach across the market and let curated stock ideas spark your next round of research.
- Target resilient balance sheets and steady cash generation through a curated list of solid balance sheet and fundamentals (23 results) that filters for financial strength first.
- Pursue value opportunities by scanning the 35 high quality undervalued stocks that highlight companies trading below their assessed quality and fundamentals.
- Hunt for potential future standouts using the 19 high quality undiscovered gems that surface quality businesses flying under most investors' radar.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com